CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...
Phase 3
Roma, Lazio, Italy and 75 other locations
to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...
Phase 3
Roma, Lazio, Italy and 73 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Roma, Italy and 228 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Roma, Italy and 508 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Rome, Italy and 508 other locations
with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...
Phase 3
Roma, RM, Italy and 76 other locations
with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...
Phase 3
Roma, Italy and 360 other locations
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...
Phase 3
Roma, Italy and 285 other locations
monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...
Phase 2
Roma, Italy and 140 other locations
with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in particip....
Phase 1, Phase 2
Roma, Italy and 46 other locations
Clinical trials
Research sites
Resources
Legal